The Charité - Universitätsmedizin Berlin is a joint medical faculty, which serves both Freie Universität Berlin and Humboldt Universität zu Berlin. As one of the largest university hospitals in Europe with an important history, it plays a leading role in research, teaching and clinical care. The Charité university hospital has also made a name for itself as a modern business with certifications in the medical, clinical and management fields.
Scientific staff (Postdoc)
We are interested in genetic programs and defects therein, which impact on tumor development and sensitivity to anticancer therapies, in particular cellular senescence, apoptosis and autophagy. We utilize transgenic mouse lymphoma (and other cancer) models with and without defined genetic lesions to dissect molecular mechanisms and to explore drug responsiveness in vivo by multiple omics techniques (genomics, transcriptomics, proteomics and metabolomcs) in a clinical trial-like format. This strategy is embedded in functional in vitro and in vivo investigations of primary human tumor material, especially lymphomas, in short-term culture and as patient-derived xenografts.
Your area of responsibilities:
Cancer models and multiomics analysis
Currently available position is embedded in a project aiming to establish innovative non-animal model systems for cancer research. Experience in mouse models and multiomics, particularly single-cell analysis, are not required but would be higly valued. Specific experimental approaches focus on (epi-)genetics, signaling, metabolism, stemness, plasticity and immunogenicity. Our central aim is to understand the role of altered cellular states in cancer biology and clinical presentation, and to convert molecular vulnerabilities identified in these test platforms into conceptually novel anticancer therapies.
For information in greater detail please see, for example, publications from our lab such as Milanovic-M et al., Nature 2018, Yu-Y et al., Cancer Cell 2018, Jing-D et al., Blood 2017 or Dörr-JR et al., Nature 2013, and recent review articles by Milanovic-M et al. (Trends Cell Biol 2019) or Lee-S and Schmitt-CA (Nat Cell Biol 2019). Our study group is co-affiliated with the Department of Hematology, Oncology and Tumor Immunology at the Charité - University Medical Center (Humboldt University and Free University) and the Max-Delbrück-Center for Molecular Medicine (MDC) in Berlin.Moreover, we are partner in the interdisciplinary German Cancer Consortium (GCC) for Translational Cancer Research, the International Graduate Program “Berlin School of Integrative Oncology (BSIO)” and other consortia with a focus on computational biology. Berlin is the place to conduct innovative and interdisciplinary research, provides a very international environment and high life quality, and is one of the most vibrant cities in Europe.
Join our highly motivated team if you are interested in systems medicine-driven approaches and novel strategies to dissect treatment- and outcome-relevant signaling modules and cell states in cancer. You hold a Ph.D. or equivalent, and you are familiar with all basic techniques in molecular biology, biochemistry and histology (i.e. cloning and genetic modifications like CRISPR, analyses of proteins and DNA/RNA, cell culture, and immunohistochemistry). Experience with mouse models and computational analysis would be highly valued. Lab communication is in English.
How to apply:
Please send your CV including a list of publications and two references/letters of recommendation to
Prof. Dr. Clemens A. Schmitt, M.D.
Charité/Campus Virchow/Hematology-Oncology, and
Max-Delbrück-Center for Molecular Medicine
Augustenburger Platz 1
DIE CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN makes its human resources decisions based on suitability, competence and professional performance. At the same time, it strives to increase the percentage of women in management positions and takes this into consideration where candidates are equally qualified within the limits of what is legally possible. Applications from people with a migrant background are also explicitly welcome. Severely disabled applicants are given preferential consideration in the case of candidates with equal qualifications. An extended certificate of conduct must be submitted. Any travel expenses incurred cannot be reimbursed.